Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon

VigiLanz Platform Earns Meaningful Use Stage 3 Certification for Antimicrobial Use and Resistance Reporting

VigiLanz, a digital healthcare intelligence firm, announced today that its antimicrobial stewardship platform has earned Meaningful Use Stage 3 (MU3) certification validating its ability to collect and properly report data around antimicrobial use and resistance.

Machine learning, AI are coming for healthcare

Machine learning and artificial intelligence (AI) are playing increasing large roles in technological developments in healthcare. Megan Williams, of Samsung Business Insights, examines how machine learning will impact the industry. 

Thumbnail

HHS Secretary Price encourages states to use ACA waivers for reinsurance, high-risk pools

While supporting the current proposal to repeal and replace the Affordable Care Act (ACA), HHS Secretary Tom Price, MD, encouraged states to submit more “innovation waivers” as allowed under the ACA to form their own reinsurance programs and fund pools to cover high-cost patients.

‘Patients before politics': AMA launches site focused on ACA repeal debate

After coming out in opposition to the American Health Care Act (AHCA), the Republican-sponsored plan to replace the Affordable Care Act (ACA), the American Medical Association (AMA) is stepping up efforts to get physicians involved in the legislative conversation through a new website.

Thumbnail

Anthem supports ACA replacement legislation

The second-largest health insurer in the U.S., Anthem, has come out in support of provisions in the Republican-sponsored replacement for the Affordable Care Act (ACA), going against the opposition expressed by the American Medical Association (AMA) and concerns from its own industry group. 

How Trump’s FDA nominee may change the agency

Gaining insight into the views of Scott Gottlieb, President Donald Trump’s pick for commissioner of the Food and Drug Administration (FDA), doesn’t take much digging, as he’s been a contributor to Forbes for years on health policy.

Simplifeye delivers patient information to a physician's wrist with the Apple Watch

Catching up on patient information costs physician an extra 15 minutes, delaying direct care time and increasing wait times. As a way for clinicians to keep patient information close Zach and Ryan Hungate developed Simplifeye, bringing patient data to clinician’s wrists through an Apple Watch.

The potential impact of the Republican ACA replacement

Health policy analyses predict 15 million people could lose their health coverage and 30 million could be subject to surcharges on top of premiums if the Republican-sponsored American Health Care Act (AHCA) goes into effect.

Displaying 4873 - 4880 of 6645

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup